Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping.

Sources (9)

• 
  Pfizer expands multibillion-dollar cost-cutting plan BioPharma Dive · 48d ago
• 
  Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics Yahoo Finance · 48d ago
• 
  Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue Yahoo Finance · 48d ago
• 
  Pfizer unveils additional $2.5B in planned cost savings through 2029 Fierce Pharma · 48d ago
• 
  Pfizer Raises Sales Guidance on High Demand for Older Drugs bloomberg.com · 48d ago
• 
  Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts Reuters · 48d ago
• 
  Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs WSJ · 48d ago
• 
  Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs CNBC · 48d ago
• 
  Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping. Barron's · 48d ago broke it first

How fast it spread

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

From around our network

• Long COVID Brain Scans Reveal Damage to Dopamine Neurons world-today-news.com
• Why Larry Ellison's Scrapped $7.5 Billion Stock Sale Was Never a Secret daybreakwire.com

Related trends